[
  {
    "ts": null,
    "headline": "Amgen (NasdaqGS:AMGN) Gains FDA Approval For UPLIZNA In Treating IgG4-Related Disease",
    "summary": "Amgen (NasdaqGS:AMGN) experienced a significant 18.62% price increase over the last quarter, coinciding with the recent FDA approval of UPLIZNA for treating Immunoglobulin G4-related disease (IgG4-RD). This approval, alongside the Breakthrough Therapy Designation granted by the FDA, reflects high unmet medical needs being addressed, which could have positively influenced investor sentiment. Despite broader market declines, including a 5% drop in the Nasdaq Composite due to trade tensions,...",
    "url": "https://finnhub.io/api/news?id=07312ce399cf21bd99d0ea95c52bdb964de0b370715a519c3744f4ac9758b045",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1743788064,
      "headline": "Amgen (NasdaqGS:AMGN) Gains FDA Approval For UPLIZNA In Treating IgG4-Related Disease",
      "id": 133727339,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "AMGN",
      "source": "Yahoo",
      "summary": "Amgen (NasdaqGS:AMGN) experienced a significant 18.62% price increase over the last quarter, coinciding with the recent FDA approval of UPLIZNA for treating Immunoglobulin G4-related disease (IgG4-RD). This approval, alongside the Breakthrough Therapy Designation granted by the FDA, reflects high unmet medical needs being addressed, which could have positively influenced investor sentiment. Despite broader market declines, including a 5% drop in the Nasdaq Composite due to trade tensions,...",
      "url": "https://finnhub.io/api/news?id=07312ce399cf21bd99d0ea95c52bdb964de0b370715a519c3744f4ac9758b045"
    }
  },
  {
    "ts": null,
    "headline": "AMGN's Uplizna Gets FDA Nod for 2nd Rare Autoimmune Disease Indication",
    "summary": "The FDA approves Amgen's Uplizna as the first and only drug for the treatment of immunoglobulin G4-related disease.",
    "url": "https://finnhub.io/api/news?id=75ecef9823a6f088fbc166be77930099f4f14544214594c0844f4d8eafa735f4",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1743786600,
      "headline": "AMGN's Uplizna Gets FDA Nod for 2nd Rare Autoimmune Disease Indication",
      "id": 133727340,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "AMGN",
      "source": "Yahoo",
      "summary": "The FDA approves Amgen's Uplizna as the first and only drug for the treatment of immunoglobulin G4-related disease.",
      "url": "https://finnhub.io/api/news?id=75ecef9823a6f088fbc166be77930099f4f14544214594c0844f4d8eafa735f4"
    }
  },
  {
    "ts": null,
    "headline": "Tariffs Hit Retail And Tech: Who's Ready To Make A Deal",
    "summary": "Trump's tariffs on 185 nations spark a $2T market drop. Click here to find out more on Market Outlook.",
    "url": "https://finnhub.io/api/news?id=93566e9d00c13e1b605c830f052f2623d26da46a9272cea0ee1f2d648dd503ad",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1743780793,
      "headline": "Tariffs Hit Retail And Tech: Who's Ready To Make A Deal",
      "id": 133721458,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/458990823/image_458990823.jpg?io=getty-c-w1536",
      "related": "AMGN",
      "source": "SeekingAlpha",
      "summary": "Trump's tariffs on 185 nations spark a $2T market drop. Click here to find out more on Market Outlook.",
      "url": "https://finnhub.io/api/news?id=93566e9d00c13e1b605c830f052f2623d26da46a9272cea0ee1f2d648dd503ad"
    }
  },
  {
    "ts": null,
    "headline": "The Dow Needs a Refresh. These Stocks Could Make It Sing.",
    "summary": "The Dow Needs a Refresh. These Stocks Could Make It Sing.",
    "url": "https://finnhub.io/api/news?id=ed979c1be51b6f4e36b244296192a0879ec1626d908a150d5c1807c8e0828131",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1743770520,
      "headline": "The Dow Needs a Refresh. These Stocks Could Make It Sing.",
      "id": 134147471,
      "image": "",
      "related": "AMGN",
      "source": "MarketWatch",
      "summary": "The Dow Needs a Refresh. These Stocks Could Make It Sing.",
      "url": "https://finnhub.io/api/news?id=ed979c1be51b6f4e36b244296192a0879ec1626d908a150d5c1807c8e0828131"
    }
  },
  {
    "ts": null,
    "headline": "The Dow Needs A Refresh. These New Members Could Make It Sing.",
    "summary": "The Dow Needs A Refresh. These New Members Could Make It Sing.",
    "url": "https://finnhub.io/api/news?id=3d6554a3ee4be23548cff7240559fbc9b1ccde4e985b0736410c967ff3f4316f",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1743770520,
      "headline": "The Dow Needs A Refresh. These New Members Could Make It Sing.",
      "id": 133720150,
      "image": "",
      "related": "AMGN",
      "source": "MarketWatch",
      "summary": "The Dow Needs A Refresh. These New Members Could Make It Sing.",
      "url": "https://finnhub.io/api/news?id=3d6554a3ee4be23548cff7240559fbc9b1ccde4e985b0736410c967ff3f4316f"
    }
  },
  {
    "ts": null,
    "headline": "11 Stocks to Buy After the Biotech Bloodbath",
    "summary": "11 Stocks to Buy After the Biotech Bloodbath",
    "url": "https://finnhub.io/api/news?id=4bb471eee97fd8116e164d1e77a79cf225956489e9eb58d8eee030df5da0a957",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1743728400,
      "headline": "11 Stocks to Buy After the Biotech Bloodbath",
      "id": 134147659,
      "image": "",
      "related": "AMGN",
      "source": "MarketWatch",
      "summary": "11 Stocks to Buy After the Biotech Bloodbath",
      "url": "https://finnhub.io/api/news?id=4bb471eee97fd8116e164d1e77a79cf225956489e9eb58d8eee030df5da0a957"
    }
  }
]